Journal Home > Volume 16 , Issue 1
Nano Research 2023, 16(1): 925-937 https://doi.org/10.1007/s12274-022-4808-2
Research Article | Issue | Published: 08 September 2022

Oral nanoparticles containing naringenin suppress atherosclerotic progression by targeting delivery to plaque macrophages

Show Author's Information Mengran Guo1,§,  Zhongshan He1,§,  Zhaohui Jin1,§,  Lingjing Huang1,  Jingmei Yuan1,  Shugang Qin1,  Xinchun Wang2,  Lili Cao3,  Xiangrong Song1( )
Department of Critical Care Medicine, Department of Anesthesiology and Translational Neuroscience Center, Department of Clinical Pharmacy, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610000, China
First Affiliated Hospital of the Medical College, Shihezi University, Shihezi 832008, China
College of Medicine, Chengdu University, Chengdu 610000, China

§ Mengran Guo, Zhongshan He, and Zhaohui Jin contributed equally to this work.

Keywords:
atherosclerosis, macrophages, oral delivery, Peyer’s patches, folic acid, naringenin
Topics:
Targeted drug delivery
Cite this article:
Guo M, He Z, Jin Z, et al. Oral nanoparticles containing naringenin suppress atherosclerotic progression by targeting delivery to plaque macrophages. Nano Research, 2023, 16(1): 925-937. https://doi.org/10.1007/s12274-022-4808-2
Download citation
EndNote(RIS)
BibTeX

735

Views

54

Downloads

Citations

6

Crossref

5

WoS

6

Scopus

0

CSCD

Abstract Full text Electronic supplementary material About this article

Atherosclerosis is the main cause of ischemic stroke and myocardial infarction diseases. Nanoparticles have shown unique benefits for atherosclerosis treatment by targeting the lesional macrophages of plaques. However, most of the nanocarriers are administered intravenously, which is inconvenient and may cause complications. Herein, we developed an oral lipid-polymer based nanoparticles (FA-LNPs) decorated with folic acid, which can not only effectively overcome intestinal mucosal-epithelial barrier by increasing the transmembrane transport through intestinal epithelial and the accumulation in Peyer’s patches but also actively target to the aortic plaque sites and accumulate in lesional macrophages. Subsequently, naringenin (Nrg), one of the anti-inflammation drugs, was designed to be the oral nanomedicine (FA-LNPs/Nrg) for the first time via the encapsulation of FA-LNPs. FA-LNPs/Nrg presented highly anti-atherosclerotic efficacy. After the atherosclerotic ApoE−/− mice were treated by FA-LNPs/Nrg via oral administration for three months, the aortic lesion area, plaque area, and necrotic core area of the aortic root were significantly decreased. Meanwhile, the lipid-related blood parameters recovered to normal levels. Our study provides a promising approach to atherosclerosis treatment based on the novel oral targeting delivery system.


menu
Abstract
Full text
Outline
Electronic supplementary material
About this article

Oral nanoparticles containing naringenin suppress atherosclerotic progression by targeting delivery to plaque macrophages

Show Author's information Mengran Guo1,§, Zhongshan He1,§, Zhaohui Jin1,§, Lingjing Huang1, Jingmei Yuan1, Shugang Qin1, Xinchun Wang2, Lili Cao3, Xiangrong Song1( )
Department of Critical Care Medicine, Department of Anesthesiology and Translational Neuroscience Center, Department of Clinical Pharmacy, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610000, China
First Affiliated Hospital of the Medical College, Shihezi University, Shihezi 832008, China
College of Medicine, Chengdu University, Chengdu 610000, China

§ Mengran Guo, Zhongshan He, and Zhaohui Jin contributed equally to this work.

Abstract

Atherosclerosis is the main cause of ischemic stroke and myocardial infarction diseases. Nanoparticles have shown unique benefits for atherosclerosis treatment by targeting the lesional macrophages of plaques. However, most of the nanocarriers are administered intravenously, which is inconvenient and may cause complications. Herein, we developed an oral lipid-polymer based nanoparticles (FA-LNPs) decorated with folic acid, which can not only effectively overcome intestinal mucosal-epithelial barrier by increasing the transmembrane transport through intestinal epithelial and the accumulation in Peyer’s patches but also actively target to the aortic plaque sites and accumulate in lesional macrophages. Subsequently, naringenin (Nrg), one of the anti-inflammation drugs, was designed to be the oral nanomedicine (FA-LNPs/Nrg) for the first time via the encapsulation of FA-LNPs. FA-LNPs/Nrg presented highly anti-atherosclerotic efficacy. After the atherosclerotic ApoE−/− mice were treated by FA-LNPs/Nrg via oral administration for three months, the aortic lesion area, plaque area, and necrotic core area of the aortic root were significantly decreased. Meanwhile, the lipid-related blood parameters recovered to normal levels. Our study provides a promising approach to atherosclerosis treatment based on the novel oral targeting delivery system.

Keywords: atherosclerosis, macrophages, oral delivery, Peyer’s patches, folic acid, naringenin

References(33)

[1]

Virani, S. S.; Alonso, A.; Benjamin, E. J.; Bittencourt, M. S.; Callaway, C. W.; Carson, A. P.; Chamberlain, A. M.; Chang, A. R.; Cheng, S. S.; Delling, F. N. et al. Heart disease and stroke statistics-2020 update: A report from the american heart association. Circulation 2020, 141, e139–e596.
DOI Google Scholar
[2]

Roy, P.; Orecchioni, M.; Ley, K. How the immune system shapes atherosclerosis: Roles of innate and adaptive immunity. Nat. Rev. Immunol. 2022, 22, 251–265.
DOI Google Scholar
[3]

He, H. L.; Wang, J.; Yannie, P. J.; Korzun, W. J.; Yang, H.; Ghosh, S. Nanoparticle-based “two-pronged” approach to regress atherosclerosis by simultaneous modulation of cholesterol influx and efflux. Biomaterials 2020, 260, 120333.
DOI Google Scholar
[4]

Wei, X. L.; Ying, M.; Dehaini, D.; Su, Y. Y.; Kroll, A. V.; Zhou, J. R.; Gao, W. W.; Fang, R. H.; Chien, S.; Zhang, L. F. Nanoparticle functionalization with platelet membrane enables multifactored biological targeting and detection of atherosclerosis. ACS Nano 2018, 12, 109–116.
DOI Google Scholar
[5]

Pham, L. M.; Kim, E. C.; Ou, W. Q.; Phung, C. D.; Nguyen, T. T.; Pham, T. T.; Poudel, K.; Gautam, M.; Nguyen, H. T.; Jeong, J. H. et al. Targeting and clearance of senescent foamy macrophages and senescent endothelial cells by antibody-functionalized mesoporous silica nanoparticles for alleviating aorta atherosclerosis. Biomaterials 2021, 269, 120677.
DOI Google Scholar
[6]

Kanthi, Y.; De La Zerda, A.; Smith, B. R. Nanotherapeutic shots through the heart of plaque. ACS Nano 2020, 14, 1236–1242.
DOI Google Scholar
[7]

Chen, L.; Jiang, Z.; Akakuru, O. U.; Yang, L.; Li, J.; Ma, S.; Wu, A. Recent progress in the detection and treatment of atherosclerosis by nanoparticles. Mater. Today Chem. 2020, 17, 100280.
DOI Google Scholar
[8]

Simin, D.; Milutinović, D.; Turkulov, V.; Brkić, S. Incidence, severity and risk factors of peripheral intravenous cannula-induced complications: An observational prospective study. J. Clin. Nurs. 2019, 28, 1585–1599.
DOI Google Scholar
[9]

Du, Y. Q.; Tian, C. T.; Wang, M. L.; Huang, D.; Wei, W.; Liu, Y.; Li, L.; Sun, B. J.; Kou, L. F.; Kan, Q. M. et al. Dipeptide-modified nanoparticles to facilitate oral docetaxel delivery: New insights into PepT1-mediated targeting strategy. Drug Deliv. 2018, 25, 1403–1413.
DOI Google Scholar
[10]

Wu, L.; Liu, M.; Shan, W.; Zhu, X.; Li, L. J.; Zhang, Z. R.; Huang, Y. Bioinspired butyrate-functionalized nanovehicles for targeted oral delivery of biomacromolecular drugs. J. Control. Release 2017, 262, 273–283.
DOI Google Scholar
[11]

Zhang, L. P.; Shi, Y. N.; Song, Y. N.; Duan, D. Y.; Zhang, X. M.; Sun, K. X.; Li, Y. X. Tf ligand-receptor-mediated exenatide-Zn2+ complex oral-delivery system for penetration enhancement of exenatide. J. Drug Target. 2018, 26, 931–940.
DOI Google Scholar
[12]

Verma, A.; Sharma, S.; Gupta, P. K.; Singh, A.; Teja, B. V.; Dwivedi, P.; Gupta, G. K.; Trivedi, R.; Mishra, P. R. Vitamin B12 functionalized layer by layer calcium phosphate nanoparticles: A mucoadhesive and pH responsive carrier for improved oral delivery of insulin. Acta Biomater. 2016, 31, 288–300.
DOI Google Scholar
[13]

Cheng, H. B.; Guo, S.; Cui, Z. X.; Zhang, X.; Huo, Y. N.; Guan, J.; Mao, S. R. Design of folic acid decorated virus-mimicking nanoparticles for enhanced oral insulin delivery. Int. J. Pharm. 2021, 596, 120297.
DOI Google Scholar
[14]

El Leithy, E. S.; Abdel-Bar, H. M.; Ali, R. A. M. Folate-chitosan nanoparticles triggered insulin cellular uptake and improved in vivo hypoglycemic activity. Int. J. Pharm. 2019, 571, 118708.
DOI Google Scholar
[15]

Naserifar, M.; Hosseinzadeh, H.; Abnous, K.; Mohammadi, M.; Taghdisi, S. M.; Ramezani, M.; Alibolandi, M. Oral delivery of folate-targeted resveratrol-loaded nanoparticles for inflammatory bowel disease therapy in rats. Life Sci. 2020, 262, 118555.
DOI Google Scholar
[16]

Elz, A. S.; Trevaskis, N. L.; Porter, C. J. H.; Bowen, J. M.; Prestidge, C. A. Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport. J. Control. Release 2022, 341, 676–701.
DOI Google Scholar
[17]

Khadke, S.; Roces, C. B.; Cameron, A.; Devitt, A.; Perrie, Y. Formulation and manufacturing of lymphatic targeting liposomes using microfluidics. J. Control. Release 2019, 307, 211–220.
DOI Google Scholar
[18]

Subramanian, P. Lipid-based nanocarrier system for the effective delivery of nutraceuticals. Molecules 2021, 26, 5510.
DOI Google Scholar
[19]

Moore, K. J.; Sheedy, F. J.; Fisher, E. A. Macrophages in atherosclerosis: A dynamic balance. Nat. Rev. Immunol. 2013, 13, 709–721.
DOI Google Scholar
[20]

Moore, K. J.; Koplev, S.; Fisher, E. A.; Tabas, I.; Björkegren, J. L. M.; Doran, A. C.; Kovacic, J. C. Macrophage trafficking, inflammatory resolution, and genomics in atherosclerosis: JACC macrophage in CVD series (part 2). J. Am. Coll. Cardiol. 2018, 72, 2181–2197.
DOI Google Scholar
[21]

Barrett, T. J. Macrophages in atherosclerosis regression. Arterioscler. Thromb. Vasc. Biol. 2020, 40, 20–33.
DOI Google Scholar
[22]

Li, W. S.; Wang, C. Y.; Peng, J. Y.; Liang, J.; Jin, Y.; Liu, Q.; Meng, Q.; Liu, K. X.; Sun, H. J. Naringin inhibits TNF-α induced oxidative stress and inflammatory response in HUVECs via Nox4/NF-κB and PI3K/Akt pathways. Curr. Pharm. Biotechnol. 2014, 15, 1173–1182.
DOI Google Scholar
[23]

Li, Z. L.; Yang, B. C.; Gao, M.; Xiao, X. F.; Zhao, S. P.; Liu, Z. L. Naringin improves sepsis-induced intestinal injury by modulating macrophage polarization via PPARγ/miR-21 axis. Mol. Ther. Nucleic Acids 2021, 25, 502–514.
DOI Google Scholar
[24]

Tahara, K.; Sakai, T.; Yamamoto, H.; Takeuchi, H.; Kawashima, Y. Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery. Int. J. Pharm. 2008, 354, 210–216.
DOI Google Scholar
[25]

Zhang, L. F.; Chan, J. M.; Gu, F. X.; Rhee, J. W.; Wang, A. Z.; Radovic-Moreno, A. F.; Alexis, F.; Langer, R.; Farokhzad, O. C. Self-assembled lipid-polymer hybrid nanoparticles: A robust drug delivery platform. ACS Nano 2008, 2, 1696–1702.
DOI Google Scholar
[26]

Xu, Q. G.; Ensign, L. M.; Boylan, N. J.; Schön, A.; Gong, X. Q.; Yang, J. C.; Lamb, N. W.; Cai, S. T.; Yu, T.; Freire, E. et al. Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo. ACS Nano 2015, 9, 9217–9227.
DOI Google Scholar
[27]

Wang, Y.; Zhao, Y. T.; Cui, Y.; Zhao, Q. F.; Zhang, Q.; Musetti, S.; Kinghorn, K. A.; Wang, S. L. Overcoming multiple gastrointestinal barriers by bilayer modified hollow mesoporous silica nanocarriers. Acta Biomater. 2018, 65, 405–416.
DOI Google Scholar
[28]

Ravar, F.; Saadat, E.; Gholami, M.; Dehghankelishadi, P.; Mahdavi, M.; Azami, S.; Dorkoosh, F. A. Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation. J. Control. Release 2016, 229, 10–22.
DOI Google Scholar
[29]

Danhier, F.; Ansorena, E.; Silva, J. M.; Coco, R.; Le Breton, A.; Préat, V. PLGA-based nanoparticles:An overview of biomedical applications. J. Control. Release 2012, 161, 505–522.
DOI Google Scholar
[30]

Lipka, J.; Semmler-Behnke, M.; Sperling, R. A.; Wenk, A.; Takenaka, S.; Schleh, C.; Kissel, T.; Parak, W. J.; Kreyling, W. G. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials 2010, 31, 6574–6581.
DOI Google Scholar
[31]

Lee, H. W.; Choi, H. J.; Ha, S. J.; Lee, K. T.; Kwon, Y. G. Recruitment of monocytes/macrophages in different tumor microenvironments. Biochim. Biophys. Acta Rev. Cancer 2013, 1835, 170–179.
DOI Google Scholar
[32]

Guo, J. W.; Li, D. D.; Tao, H.; Li, G.; Liu, R. F.; Dou, Y.; Jin, T. T.; Li, L. L.; Huang, J.; Hu, H. Y. et al. Cyclodextrin-derived intrinsically bioactive nanoparticles for treatment of acute and chronic inflammatory diseases. Adv. Mater. 2019, 31, 1904607.
DOI Google Scholar
[33]

Burke, A. C.; Sutherland, B. G.; Telford, D. E.; Morrow, M. R.; Sawyez, C. G.; Edwards, J. Y.; Huff, M. W. Naringenin enhances the regression of atherosclerosis induced by a chow diet in Ldlr−/− mice. Atherosclerosis 2019, 286, 60–70.
DOI Google Scholar
File
12274_2022_4808_MOESM1_ESM.pdf (427.7 KB)
Publication history
Copyright
Acknowledgements

Publication history

Received: 04 May 2022
Revised: 24 July 2022
Accepted: 25 July 2022
Published: 08 September 2022
Issue date: January 2023

Copyright

© Tsinghua University Press 2022

Acknowledgements

Acknowledgements

This study was supported by the Youth Fund of National Natural Science Foundation of China (No. 82104081), Sichuan Province Science and Technology Support Program (No. 2020JDRC0052), the 1.3.5 Project for Disciplines of excellence, West China Hospital, Sichuan University (No. ZYGD18020/ZYJC18006), and Science and Technology Project of Xinjiang Production and Construction Corps (No. 2022AB020).

Return